Biomarkers in carcinoma of the cervix: Emphasis on tissue-related factors and their potential prognostic factors

Annals of the Academy of Medicine Singapore

Volumn 27, Issue 5, 1998, Pages 671-675

  Busmanis, Inny ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Human papillomavirus; Oncogenes; Proliferation markers

Indexed keywords

CYCLINE; KI 67 ANTIGEN; ONCOPROTEIN; PROTEINASE; TUMOR MARKER;

FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; ONCOGENE; REVIEW; UTERINE CERVIX TUMOR;

ENDOPEPTIDASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; ONCOGENE PROTEINS; ONCOGENES; PROLIFERATING CELL NUCLEAR ANTIGEN; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 0032153269     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Sevin B-U, Nadji M, Lampe B, Lu Y, Hilsenbeck S, Koechli O R. Prognostic factors of early stage cervical carcinoma treated by radical hysterectomy. Cancer 1995; 76:1978-86.
2. Rosai J, editor. Ackerman's Surgical Pathology. USA: Mosby-Year Book, 1996:1367.
3. Dellas A, Moch H, Schultheiss E, Feichter G, Almendral A, Gudat F, et al. Angiogenesis in cervical neoplasia: microvessel quantitation in precancerous lesions and invasive carcinomas with clinicopathological correlations. Gynecol Oncol 1997; 67:27-33.
4. Schlenger K, Hockel M, Mitze M, Schaffer V, Weikel W, Knapstein P G, et al. Tumour vascularity - a novel prognostic factor in advanced cervical carcinoma. Gynecol Oncol 1995; 59:57-66.
5. Wiggins D L, Grandi C O, Steinhoff M M, Calabresi P. Tumor angiogenesis as a prognostic factor in cervical carcinoma. Gynecol Oncol 1995; 56:353-6.
6. Ryan K M, Birnie G D. Myc oncogenes: the enigmatic family. Biochem J 1996; 314(Pt3):713-21.
7. Devictor B, Bonnier P, Piana L, Andrac L, Lavaut M-N, Allasia C, et al. C-myc protein and Ki-67 antigen immunodetection in patients with uterine cervix neoplasia: correlation of microcytophotometric analysis and histological data. Gynecol Oncol 1993; 49:284-90.
8. Baker V, Hatch K, Shingleton H. Amplification of the c-myc proto-oncogene in cervical carcinoma. J Surg Oncol 1988; 39:225-8.
9. Ocadiz R, Sauceda R, Cruz M, Graef M, Graef A, Gariglio P. High correlation between molecular alterations of the c-myc oncogene and carcinoma of the uterine cervix. Cancer Res 1987; 47:4173-7.
10. Di Luca D, Costa S, Monini P, Rotola A, Terzano P, Savioli A, et al. Search for human papillomavirus, herpes simplex virus and c-myc oncogene in human genital tumors. Int J Cancer 1989; 43:570-7.
11. Sowani A, Ong G, Dische S, Quinn C, White J, Soutter P, et al. C-myc oncogene expression and clinical outcome in carcinoma of the cervix. Mol Cell Probes 1989; 3:117-23.
12. Bourhis J, Le M G, Barrois M, Gerbaulet A, Jeannel D, Duvillard P, et al. Prognostic value of c-myc proto-oncogene overexpression in early invasive carcinoma of the cervix. J Clin Oncol 1990; 8:1789-96.
13. Riou G, Barrois M, Le M G, George M, LeDoussal V, Haie C. C-myc protooncogene expression and prognosis in early carcinoma of the uerine cervix. Lancet 1987; 1:761-3.
14. Symonds R P, Habeshaw T, Paul J, Kerr D J, Darling A, Burnett R A, et al. No correlation between ras, c-myc and c-jun proto-oncogene expression and prognosis in advanced carcinoma of cervix. Eur J Cancer 1992; 28A:1615-7.
15. Grendys E C Jr, Barnes W A, Weitzel J, Sparkowski J, Schlegel R. Identification of H, K and N-ras point mutations in stage IB cervical carcinoma. Gynecol Oncol 1997; 65:343-7.
16. Sagae S, Kuzumaki N, Hisada T, Mugikura Y, Kudo R, Hshimoto M. Ras oncogene expression and prognosis of invasive squamous cell carcinomas of the uterine cervix. Cancer 1989; 63:82.
17. Agnantis N J, Spandidas D A, Mahera H. Immunohistochemical study of ras oncogene expression in endometrial and cervical human lesions. Eur Gynaecol Oncol 1988; 9:360-5.
18. Hayashi Y, Hachisuga T, Iwasaka T, Fukuda K, Okuma Y, Yokoyama M. Expression of ras oncogene product and EGF receptor in cervical squamous cell carcinomas and its relationship to lymph node involvement. Gynecol Oncol 1991; 40:147-51.
19. Costa M J, Walls J, Trelford J D. CerbB2 oncoprotein overexpression in uterine cervix carcinoma with gladular differentiation. A frequent event but not an independent prognostic marker because it occurs late in the disease. Am J Clin Pathol 1995; 104:634-42.
20. Oka K, Nakano T, Arai T. CerbB2 oncoprotein expression is associated with poor prognosis in squamous cell carcinoma of the cervix. Cancer 1994; 73:664-71.
21. Kristensen G B, Holm R, Abeler V M, Trope C G. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and cerbB2 in early cervical squamous cell carcinoma: an immunohistochemical study. Cancer 1996; 78:433-40.
22. Hale R J, Buckley C H, Fox H, Williams J. Prognostic value of c-erbB-2 expression in uterine cervical carcinoma. J Clin Pathol 1992; 45:594-6.
23. Nakano T, Oka K, Ishikawa A, Morita S. Correlation of cervical carcinoma c-erbB-2 oncogene with cell proliferation parameters in patients treated with radiation therapy for cervical carcinoma. Cancer 1997; 79:513-20.
24. Dellas A, Schultheiss E, Almendral A C, Torhorst J, Gudat F. Assessment of EGFR and TGF-alpha expression in relationship to HPV status and Ki-67 distribution in cervical intraepithelial neoplasms. Int J Cancer 1996; 69:165-9.
25. Kim J W, Kim Y T, Kim D K, Song C H, Lee J W. Expression of epidermal growth factor receptor in carcinoma of the cervix. Gynecol Oncol 1996; 60:283-7.
26. Oka K, Nakano T, Arai T. Expression of cathepsin D and epidermal growth factor receptor in stage III cervical carcinomas. Int J Gynecol Cancer 1997; 7:122-6.
27. Hale R J, Buckley C H, Gullick W J, Fox H, Williams J, Wilcox F L. Prognostic value of epidermal growth factor receptor expression in cervical carcinoma. J Clin Pathol 1993; 46:149-53.
28. Mittal K R, Lin O, Chan W, Goswami S, Demopoulos RI. Cervical squamous dysplasias and carcinomas with immunodetectable p53 frequently contain HPV. Gynecol Oncol 1995; 58:289-94.
29. Chetty R, Bramdev A, Aquirre-Arteta A, Pegoraro R J, Sataar N. Relation between retinoblastoma and p53 proteins in human papilloma viruses 16/18 positive and negative cancers of the uterine cervix. J Clin Pathol 1997; 50:413-6.
30. Kessis T D, Stebos R J, Han S M, Shah K, Bosch X F, Munoz N, et al. p53 gene mutations and MDM2 amplification are uncommon in primary carcinomas of the uterine cervix. Am J Pathol 1993; 143:1398-405.
31. Fujita M, Inoue M, Tanizawa O, Iwamoto S, Enomoto T. Alterations of the p53 gene in human primary cervical carcinoma with and without human papilloma virus infection. Cancer Res 1992; 52:5323-8.
32. Mandai M, Konishi I, Koshiyama M, Komatsu T, Yamamoto S, Nanbu K, et al. Altered expression of nm23-HI and c-erbB-2 proteins have prognostic significance in adenocarcinoma but not in squamous cell carcinoma of the uterine cervix. Cancer 1995; 75:2523-9.
33. Kristensen G B, Holm R, Abeler V M, Trope C G. Evaluation of the prognostic significance of nm23/NDP kinase protein expression in cervical carcinoma: an immunohistochemical study. Gynecol Oncol 1996; 61:378-83.
34. Zamulaeva I A, Podgorodnichenko V K, Guseva L I, Krikunova L I, Saenko A S. Prognostic significance of S-phase fraction detected by antithymidine antibodies in epidermoid cervix carcinomas. Int J Radiat Oncol Biol Phys 1996; 36:685-8.
35. Hall P A, Levison D A. Review: assessment of cell proliferation in histological material. J Clin Pathol 1990; 43:184-92.
36. Scott R J, Hall P A, Haldane J S, Van Noorden S, Price Y, Lane D P, et al. A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction. J Pathol 1991; 165:173-8.
37. Mittal K R, Demopoulos R I, Goswami S. Proliferating cell nuclear antigen (cyclin) expression in normal and abnormal cervical squamous epithelia. Am J Surg Pathol 1993; 17:117-22.
38. Shurbaji M S, Brooks S K, Thurmond T S. Proliferating cell nuclear antigen immunoreactivity in cervical intraepithelial neoplasia and benign cervical epithelium. Am J Clin Pathol 1993; 100:22-6.
39. Oka K, Hoshi T, Arai T. Prognostic significance of the PC 10 index as a prospective assay for cervical cancer treated with radiation therapy alone. Cancer 1992; 70:1545-50.
40. Al-Nafussi A I, Klys H S, Rebello G, Kelly C, Kerr G, Cowie V. The assessment of proliferating cell nuclear antigen (PCNA) immunostaining in the uterine cervix and cervical squamous neoplasia. Int J Gynecol Cancer 1993; 3:154-8.
41. Konishi I, Fujii S, Nonogaki H, Nanbu Y, Twdi T, Mori T. Immunohistochemical analysis of estrogen receptors, progesterone receptors, Ki-67 antigen, and human papilloma virus DNA in normal and neoplastic epithelium of the uterine cervix. Cancer 1991; 68:1340-50.
42. Garzetti G G, Ciavattini A, Lucarini G, Goteri G, De Nictolis M, Muzzioli M. MIBI immunostaining in stage 1 squamous cervical carcinoma: relationship with natural killer cell activity. Gynecol Oncol 1995; 58:28-33.
43. Mitchell K M, Hale R J, Buckley C H, Fox H, Smith D. Cathepsin D expression in cervical carcinoma and its prognostic significance. Virchows Arch A Pathol Anat Histopathol 1993; 422:357-60.
44. Liao S Y, Brewer C, Zavada J, Pastorek J, Pastorekova S, Manetta A, et al. Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. Am J Pathol 1994; 145:598-609.
45. Brewer C A, Liao S Y, Wilczynski S P, Pastorekova S, Pastorek J, Zavada J, et al. A study of biomarkers in cervical carcinoma and clinical correlation of the novel biomarker MN. Gynecol Oncol 1996; 63:337-44.
46. Garzetti G G, Ciavattini A, Lucarini G, Goteri G, De Nictolis M, Biagini G. Microinvasive cervical carcinoma and cervical intraepithelial neoplasia: biologic significance and clinical implications of 72-Kda metalloproteinase immunostaining. Gynecol Oncol 1996; 61:197-203.
47. Garzetti G G, Ciavattini A, Lucarini G, Goteri G, Romanini C, Biagini G. The 72-Kda metalloproteinase immunostaining in cervical carcinoma: relationship with lymph nodal involvement. Gynecol Oncol 1996; 60:271-6.